Claims for Patent: 10,092,645

Summary for Patent: 10,092,645

Title:	Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
Abstract:	This application provides a method of treating cancer in a patient comprising administering at least one dose of radiation therapy and at least one PD-1 and/or PD-L1 antagonist, wherein at least one PD-1 and/or PD-L1 antagonist is administered on the same day as a dose of radiation therapy or up to and including 4 days later.
Inventor(s):	Stewart; Ross (Cambridge, GB), Morrow; Michelle (Cambridge, GB), Wilkinson; Robert (Cambridge, GB), Poon; Edmund (Cambridge, GB), Dovedi; Simon (Manchester, GB), Illidge; Tim (Manchester, GB)
Assignee:	MedImmune Limited (Cambridge, GB)
Application Number:	14/740,876
Patent Claims:	1. A method of treating cancer in a patient comprising a. administering to the patient a fraction of fractionated radiation therapy; and b. administering to the patient at least one PD-1 and/or PD-L1 antagonist, wherein the at least one PD-1 and/or PD-L1 antagonist is administered on the same day as the fraction of radiation therapy or up to and including 4 days later, wherein the fraction is 2.2 Gy or lower, and wherein the cancer is bladder cancer, breast cancer, colorectal cancer, head and neck cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer or renal cancer. 2. The method of claim 1, wherein the at least one PD-1 and/or PD-L1 antagonist is an at least one PD-1 and/or PD-L1 antibody or functional part thereof. 3. The method of claim 1, wherein the patient is administered fractions of radiation therapy that total about 70 Gy or lower. 4. The method of claim 3, wherein the patient is administered fractions of radiation therapy that total about 50 Gy or lower. 5. The method of claim 1, wherein the fractionated radiation therapy comprises from 2 to 7 fractions. 6. The method of claim 5, wherein the fractionated radiation therapy comprises 5 fractions. 7. The method of claim 6, wherein the radiation therapy fractions are administered in sequential days. 8. The method of claim 7, wherein the radiation therapy fractions are administered on day 1, day 2, day 3, day 4, and day 5. 9. The method of claim 1, wherein the at least one PD-1 and/or PD-L1 antagonist is administered on day 1. 10. The method of claim 1, wherein the at least one PD-1 and/or PD-L1 antagonist is administered on day 5. 11. The method of claim 1, wherein the at least one PD-1 and/or PD-L1 antagonist is administered multiple times. 12. The method of claim 11, wherein the at least one PD-1 and/or PD-L1 antagonist is administered 3 times a week. 13. The method of claim 2, wherein the anti-PD-1 and/or PD-L1 antibody or functional part thereof is MEDI4736. 14. The method of claim 2, wherein the anti-PD-1 and/or anti-PD-L1 antibody or functional part thereof is pembrolizumab, nivolumab, BMS-936558, AMP-224, or MPDL3280A. 15. The method of claim 1, wherein treatment cycles are weekly or every other week. 16. The method of claim 1, wherein more than one treatment cycle is performed. 17. The method of claim 16, wherein from 2-8 treatment cycles are performed.

Details for Patent 10,092,645

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	September 04, 2014		2034-06-17
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	Injection	125514	January 15, 2015		2034-06-17
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	December 22, 2014		2034-06-17
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	October 04, 2017		2034-06-17
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	August 27, 2021		2034-06-17